

AMENDMENTS TO THE CLAIMS

Listing of Claims:

- 1-28. (Cancelled)
29. (Currently Amended) A method of treating vasculitis comprising administering an ~~interleukin-6 (IL-6) antagonist~~ antibody against interleukin (IL-6) receptor to a subject in need thereof.
30. (Withdrawn-Currently Amended) A method ~~of preventing and/or~~ treating vasculitis having resistance to steroids and/or immunosuppressants, comprising administering an ~~interleukin-6 (IL-6) antagonist~~ antibody against interleukin (IL-6) receptor to a subject in need thereof.
31. (Previously Presented) The method according to claim 29 wherein said vasculitis is polyarteritis nodosa.
32. (Withdrawn) The method according to claim 29 wherein said vasculitis is the aortitis syndrome.
33. (Withdrawn) The method according to claim 29 wherein said vasculitis is vasculitis associated with immunological abnormalities.
34. (Cancelled).
35. (Currently Amended) The method according to claim ~~34~~ 29 wherein said antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.
36. (Currently Amended) The method according to claim ~~34~~ 29 wherein said antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

37. (Withdrawn-Currently Amended) The method according to claim 34 29 wherein said antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

38. (Currently Amended) The method according to claim 34 29 wherein said antibody against IL-6 receptor is a recombinant antibody.

39. (Original) The method according to claim 36 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

40. (Withdrawn) The method according to claim 37 wherein said monoclonal antibody against mouse IL-6 receptor is MR1 antibody.

41. (Currently Amended) The method according to claim 34 29 wherein said antibody against IL-6 receptor is a chimeric antibody, humanized antibody, or a human antibody against IL-6 receptor.

42. (Original) The method according to claim 41 wherein said humanized antibody against IL-6 receptor is a humanized PM-1 antibody.